Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 184362, 8 pages
http://dx.doi.org/10.1100/2012/184362
Review Article

Progress towards Mechanism-Based Treatment for Diamond-Blackfan Anemia

Department of Molecular Medicine and Gene Therapy, 22184 Lund University, Lund, Sweden

Received 9 October 2011; Accepted 20 December 2011

Academic Editors: R. A. Brodsky, W. Fried, N. Giannakoulas, and N. Komatsu

Copyright © 2012 Sara E. Sjögren and Johan Flygare. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. Nathan, B. J. Clarke, D. G. Hillman, B. P. Alter, and D. E. Housman, “Erythroid precursors in congenital hypoplastic (Diamond-Blackfan) anemia,” Journal of Clinical Investigation, vol. 61, no. 2, pp. 489–498, 1978. View at Publisher · View at Google Scholar
  2. L. K. Diamond and K. D. Blackfan, “Hypoplastic anemia,” American Journal of Diseases of Children, vol. 56, pp. 464–467, 1938. View at Google Scholar
  3. A. Vlachos and E. Muir, “How I treat Diamond-Blackfan anemia,” Blood, vol. 116, no. 19, pp. 3715–3723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Vlachos, S. Ball, N. Dahl et al., “Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference,” British Journal of Haematology, vol. 142, no. 6, pp. 859–876, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. B. E. Glader and K. Backer, “Elevated red cell adenosine deaminase activity: a marker of disordered erythropiesis in Diamond-Blackfan anaemia and other haematologic diseases,” British Journal of Haematology, vol. 68, no. 2, pp. 165–168, 1988. View at Google Scholar · View at Scopus
  6. J. M. Lipton, E. Atsidaftos, I. Zyskind, and A. Vlachos, “Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry,” Pediatric Blood and Cancer, vol. 46, no. 5, pp. 558–564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. T. N. Willig, C. M. Niemeyer, T. Leblanc et al., “Identification of new prognosis factors from the clinical and epidemiologic analysis of a registry of 229 Diamond-Blackfan anemia patients. DBA group of Societe d'Hematologie et d'Immunologie Pediatrique (SHIP), Gesellshaft fur Padiatrische Onkologie und Hamatologie (GPOH), and the European Society for Pediatric Hematology and Immunology (ESPHI),” Pediatric Research, vol. 46, no. 5, pp. 553–561, 1999. View at Google Scholar
  8. V. Roy, W. S. Perez, M. Eapen et al., “Bone marrow transplantation for Diamond-Blackfan anemia,” Biology of Blood and Marrow Transplantation, vol. 11, no. 8, pp. 600–608, 2005. View at Publisher · View at Google Scholar
  9. N. Draptchinskaia, P. Gustavsson, B. Andersson et al., “The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia,” Nature Genetics, vol. 21, no. 2, pp. 169–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Cmejla, J. Cmejlova, H. Handrkova, J. Petrak, and D. Pospisilova, “Ribosomal protein S17 gene (RPS17) is mutated in Diamond-Blackfan anemia,” Human Mutation, vol. 28, no. 12, pp. 1178–1182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Doherty, M. R. Sheen, A. Vlachos et al., “Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia,” American Journal of Human Genetics, vol. 86, no. 2, pp. 222–228, 2010. View at Publisher · View at Google Scholar
  12. J. E. Farrar, M. Nater, E. Caywood et al., “Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blaekfan anemia,” Blood, vol. 112, no. 5, pp. 1582–1592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. H. T. Gazda, A. Grabowska, L. B. Merida-Long et al., “Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia,” American Journal of Human Genetics, vol. 79, no. 6, pp. 1110–1118, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. H. T. Gazda, M. R. Sheen, A. Vlachos et al., “Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients,” American Journal of Human Genetics, vol. 83, no. 6, pp. 769–780, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. I. Boria, E. Garelli, H. T. Gazda et al., “The ribosomal basis of Diamond-Blackfan anemia: mutation and database update,” Human Mutation, vol. 31, no. 12, pp. 1269–1279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Hamaguchi, A. Ooka, A. Brun, J. Richter, N. Dahl, and S. Karlsson, “Gene transfer improves erythroid development in ribosomal protein S19-deficient Diamond-Blackfan anemia,” Blood, vol. 100, no. 8, pp. 2724–2731, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Hamaguchi, J. Flygare, H. Nishiura et al., “Proliferation deficiency of multipotent hematopoietic progenitors in ribosomal protein S19 (RPS19)-deficient Diamond-Blackfan anemia improves following RPS19 gene transfer,” Molecular Therapy, vol. 7, no. 5, pp. 613–622, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Flygare, K. Olsson, J. Richter, and S. Karlsson, “Gene therapy of Diamond Blackfan anemia CD34(+) cells leads to improved erythroid development and engraftment following transplantation,” Experimental Hematology, vol. 36, no. 11, pp. 1428–1435, 2008. View at Google Scholar · View at Scopus
  19. J. Flygare, T. Kiefer, K. Miyake et al., “Deficiency of ribosomal protein S19 in CD34+ cells generated by siRNA blocks erythroid development and mimics defects seen in Diamond-Blackfan anemia,” Blood, vol. 105, no. 12, pp. 4627–4634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. B. L. Ebert, M. M. Lee, J. L. Pretz et al., “An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray,” Blood, vol. 105, no. 12, pp. 4620–4626, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. C. A. Sieff, J. Yang, L. B. Merida-Long, and H. F. Lodish, “Pathogenesis of the erythroid failure in Diamond Blackfan anaemia,” British Journal of Haematology, vol. 148, no. 4, pp. 611–622, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Jaako, J. Flygare, K. Olsson et al., “Chronic RPS19 deficiency leads to bone marrow failure in a mouse model for Diamond Blackfan anemia,” in Proceedings of the 52nd Annual Meeting of the American-Society-of-Hematology (ASH '10), pp. 116–193, The American Society of Hematology, Orlando, Fla, USA, 2010.
  23. Y. Ohene-Abuakwa, K. A. Orfali, C. Marius, and S. E. Ball, “Two-phase culture in Diamond Blackfan anemia: localization of erythroid defect,” Blood, vol. 105, no. 2, pp. 838–846, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Miyake, T. Utsugisawa, J. Flygare et al., “Ribosomal protein S19 deficiency leads to reduced proliferation and increased apoptosis but does not affect terminal erythroid differentiation in a cell line model of Diamond-Blackfan anemia,” Stem Cells, vol. 26, no. 2, pp. 323–329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. N. C. Jones, M. L. Lynn, K. Gaudenz et al., “Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function,” Nature Medicine, vol. 14, no. 2, pp. 125–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Dutt, A. Narla, K. Lin et al., “Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells,” Blood, vol. 117, no. 9, pp. 2567–2576, 2011. View at Publisher · View at Google Scholar
  27. J. L. Barlow, L. F. Drynan, D. R. Hewett et al., “A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome,” Nature Medicine, vol. 16, no. 1, pp. 59–66, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Danilova, K. M. Sakamoto, and S. Lin, “Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family,” Blood, vol. 112, no. 13, pp. 5228–5237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. A. M. Taylor, J. M. Humphries, R. M. White, R. D. Murphey, C. E. Burns, and L. I. Zon, “Hematopoietic defects in rps29 mutant zebrafish depend upon p53 activation,” Experimental Hematology, vol. 40, no. 3, pp. 228–237, 2012. View at Publisher · View at Google Scholar
  30. P. Jaako, J. Flygare, K. Olsson et al., “Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia,” Blood, vol. 118, no. 23, pp. 6087–6096, 2011. View at Publisher · View at Google Scholar
  31. Y. Zhang, G. W. Wolf, K. Bhat et al., “Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway,” Molecular and Cellular Biology, vol. 23, no. 23, pp. 8902–8912, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. M. S. Dai and H. Lu, “Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5,” The Journal of Biological Chemistry, vol. 279, no. 43, pp. 44475–44482, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Takagi, M. J. Absalon, K. G. McLure, and M. B. Kastan, “Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin,” Cell, vol. 123, no. 1, pp. 49–63, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. P. L. Miliani de Marval and Y. Zhang, “The RP-Mdm2-p53 pathway and tumorigenesis,” Oncotarget, vol. 2, no. 3, pp. 234–238, 2011. View at Google Scholar
  35. S. Fumagalli, A. Di Cara, A. Neb-Gulati et al., “Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translationdependent mechanism of p53 induction,” Nature Cell Biology, vol. 11, no. 4, pp. 501–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. A. McGowan, J. Z. Li, C. Y. Park et al., “Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects,” Nature Genetics, vol. 40, no. 8, pp. 963–970, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Gasser, “Aplastic anemia (chronic erythroblastophthisis) and cortisone,” Schweizerische Medizinische Wochenschrift, vol. 81, no. 50, pp. 1241–1242, 1951. View at Google Scholar · View at Scopus
  38. R. J. Calvert and T. Robson, “Cortisone therapy in erythrogenesis imperfecta,” Archives of Disease in Childhood, vol. 31, no. 157, pp. 177–181, 1956. View at Google Scholar · View at Scopus
  39. T. F. Yeh, Y. J. Lin, W. S. Hsieh et al., “Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial,” Pediatrics, vol. 100, no. 4, article E3, 1997. View at Google Scholar · View at Scopus
  40. T. F. Yeh, Y. J. Lin, C. C. Huang et al., “Early dexamethasone therapy in preterm infants: a follow-up study,” Pediatrics, vol. 101, no. 5, p. E7, 1998. View at Google Scholar · View at Scopus
  41. A. Narla, S. Dutt, J. R. McAuley et al., “Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis,” Blood, vol. 118, no. 8, pp. 2296–2304, 2011. View at Publisher · View at Google Scholar
  42. J. Flygare, V. R. Estrada, C. Shin, S. Gupta, and H. F. Lodish, “HIF1α synergizes with glucocorticoids to promote BFU-E progenitor self-renewal,” Blood, vol. 117, no. 12, pp. 3435–3444, 2011. View at Publisher · View at Google Scholar
  43. H. Lodish, J. Flygare, and S. Chou, “From stem cell to erythroblast: regulation of red cell production at multiple levels by multiple hormones,” IUBMB Life, vol. 62, no. 7, pp. 492–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Bauer, F. Tronche, O. Wessely et al., “The glucocorticoid receptor is required for stress erythropoiesis,” Genes and Development, vol. 13, no. 22, pp. 2996–3002, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Leberbauer, F. Boulme, G. Unfried, J. Huber, H. Beug, and E. W. Mullner, “Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors,” Blood, vol. 105, no. 1, pp. 85–94, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. O. Wessely, E. M. Deiner, H. Beug, and M. von Lindern, “The glucocorticoid receptor is a key regulator of the decision between self-renewal and differentiation in erythroid progenitors,” The EMBO Journal, vol. 16, no. 2, pp. 267–280, 1997. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Ganguli, J. Back, S. Sengupta, and B. Wasylyk, “The p53 tumour suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors,” EMBO Reports, vol. 3, no. 6, pp. 569–574, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. E. M. Leonard, E. Raefsky, P. Griffith, J. Kimball, A. W. Nienhuis, and N. S. Young, “Cyclosporine therapy of aplastic anaemia, congenital and acquired red cell aplasia,” British Journal of Haematology, vol. 72, no. 2, pp. 278–284, 1989. View at Google Scholar · View at Scopus
  49. A. El-Beshlawy, I. Y. Ibrahim, S. Rizk, and K. Eid, “Study of 22 Egyptian patients with Diamond-Blackfan anemia, corticosteroids, and cyclosporin therapy results,” Pediatrics, vol. 110, no. 4, p. e44, 2002. View at Google Scholar · View at Scopus
  50. M. Seip and G. F. Zanussi, “Cyclosporine in steroid-resistant Diamond-Blackfan anaemia,” Acta Paediatrica Scandinavica, vol. 77, no. 3, pp. 464–466, 1988. View at Google Scholar · View at Scopus
  51. A. T. Taher, K. M. Musallam, S. Koussa, and A. Inati, “Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy,” Annals of Hematology, vol. 88, no. 12, pp. 1263–1264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Fiorillo, V. Poggi, R. Migliorati, R. Parasole, C. Selleri, and B. Rotoli, “Letter to the editor: unresponsiveness to erythropoietin therapy in a case of Blackfan Diamond anemia,” American Journal of Hematology, vol. 37, no. 1, p. 65, 1991. View at Google Scholar · View at Scopus
  53. C. M. Niemeyer, E. Baumgarten, J. Holldack et al., “Treatment trial with recombinant human erythropoietin in children with congenital hypoplastic anemia,” Contributions to Nephrology, vol. 88, pp. 276–280, 1991. View at Google Scholar
  54. Y. Bastion, P. Bordigoni, M. Debre et al., “Sustained response after recombinant interleukin-3 in Diamond Blackfan anemia,” Blood, vol. 83, no. 2, pp. 617–618, 1994. View at Google Scholar · View at Scopus
  55. A. Ganser, A. Lindemann, G. Seipelt et al., “Effects of recombinant human interleukin-3 in aplastic anemia,” Blood, vol. 76, no. 7, pp. 1287–1292, 1990. View at Google Scholar · View at Scopus
  56. A. P. Gillio, L. B. Faulkner, B. P. Alter et al., “Treatment of Diamond-Blackfan anemia with recombinant human interleukin-3,” Blood, vol. 82, no. 3, pp. 744–751, 1993. View at Google Scholar · View at Scopus
  57. S. E. Ball, G. Tchernia, L. Wranne et al., “Is there a role for interleukin-3 in Diamond-Blackfan anaemia? Results of a European multicentre study,” British Journal of Haematology, vol. 91, no. 2, pp. 313–318, 1995. View at Google Scholar · View at Scopus
  58. S. Sumimoto, M. Kawai, Y. Kasajima, and T. Hamamoto, “Intravenous γ-globulin therapy in Diamond-Blackfan anemia,” Acta Paediatrica Japonica (Overseas Edition), vol. 34, no. 2, pp. 179–180, 1992. View at Google Scholar · View at Scopus
  59. S. M. Sopo, M. A. Pesaresi, M. Pastore, and A. Stabile, “Intravenous immunoglobulin in Diamond-Blackfan anaemia,” European Journal of Pediatrics, vol. 149, no. 11, pp. 779–780, 1990. View at Publisher · View at Google Scholar · View at Scopus
  60. J. L. Abkowitz, G. Schaison, F. Boulad et al., “Response of Diamond-Blackfan anemia to metoclopramide: evidence for a role for prolactin in erythropoiesis,” Blood, vol. 100, no. 8, pp. 2687–2691, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. T. M. Leblanc, L. Da Costa, I. Marie, P. Demolis, and G. Tchernia, “Metoclopramide treatment in DBA patients: no complete response in a French prospective study,” Blood, vol. 109, no. 5, pp. 2266–2267, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. F. I. Jabr, E. Aoun, C. Azar, and A. Taher, “Diamond-Blackfan anemia responding to valproic acid,” Blood, vol. 104, no. 10, p. 3415, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. M. J. Koury and M. C. Bondurant, “Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells,” Journal of Cellular Physiology, vol. 137, no. 1, pp. 65–74, 1988. View at Google Scholar · View at Scopus
  64. S. Eshghi, M. G. Vogelezang, R. O. Hynes, L. G. Griffith, and H. F. Lodish, “α4β1 integrin and erythropoietin mediate temporally distinct steps in erythropoiesis: integrins in red cell development,” Journal of Cell Biology, vol. 177, no. 5, pp. 871–880, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Wu, X. Liu, R. Jaenisch, and H. F. Lodish, “Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor,” Cell, vol. 83, no. 1, pp. 59–67, 1995. View at Google Scholar · View at Scopus
  66. H. S. Chan, E. F. Saunders, and M. H. Freedman, “Diamond-Blackfan syndrome—I. Erythropoiesis in prednisone responsive and resistant disease,” Pediatric Research, vol. 16, no. 6, pp. 474–476, 1982. View at Google Scholar · View at Scopus
  67. E. P. Reddy, A. Korapati, P. Chaturvedi, and S. Rane, “IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled,” Oncogene, vol. 19, no. 21, pp. 2532–2547, 2000. View at Google Scholar · View at Scopus
  68. M. S. Rinaudo, K. Su, L. A. Falk, S. Haldar, and R. A. Mufson, “Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells,” Blood, vol. 86, no. 1, pp. 80–88, 1995. View at Google Scholar · View at Scopus
  69. T. Uo, T. D. Veenstra, and R. S. Morrison, “Histone deacetylase inhibitors prevent p53-dependent and p53-independent bax-mediated neuronal apoptosis through two distinct mechanisms,” Journal of Neuroscience, vol. 29, no. 9, pp. 2824–2832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Naithani, J. Chandra, S. Narayan, V. Singh, and A. K. Dutta, “Diamond-Blackfan anemia: clinical features and treatment results in 4 cases,” Hematology, vol. 11, no. 3, pp. 193–195, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. V. C. Broudy, “Stem cell factor and hematopoiesis,” Blood, vol. 90, no. 4, pp. 1345–1364, 1997. View at Google Scholar · View at Scopus
  72. A. List, G. Dewald, J. Bennett et al., “Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1456–1465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. B. L. Ebert, J. Pretz, J. Bosco et al., “Identification of RPS14 as a 5q-syndrome gene by RNA interference screen,” Nature, vol. 451, no. 7176, pp. 335–339, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Y. Lee, S. D. Jo, J. H. Lee, and H. J. Han, “L-leucine increases [3H]-thymidine incorporation in chicken hepatocytes: involvement of the PKC, PI3K/Akt, ERK1/2, and mTOR signaling pathways,” Journal of Cellular Biochemistry, vol. 105, no. 6, pp. 1410–1419, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Singh, A. Akcakanat, C. Sharma, D. Luyimbazi, K. A. Naff, and F. Meric-Bernstam, “The effect of leucine restriction on Akt/mTOR signaling in breast cancer cell lines in vitro and in vivo,” Nutrition and Cancer, vol. 63, no. 2, pp. 264–271, 2011. View at Publisher · View at Google Scholar
  76. S. R. Kimball and L. S. Jefferson, “Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis,” Journal of Nutrition, vol. 136, Supplement 1, pp. 227S–231S, 2006. View at Google Scholar · View at Scopus
  77. J. Cmejlova, L. Dolezalova, D. Pospisilova, K. Petrtylova, J. Petrak, and R. Cmejla, “Translational efficiency in patients with Diamond-Blackfan anemia,” Haematologica, vol. 91, no. 11, pp. 1456–1464, 2006. View at Google Scholar · View at Scopus
  78. D. Pospisilova, J. Cmejlova, J. Hak, T. Adam, and R. Cmejla, “Successful treatment of a Diamond-Blackfan anemia patient with amino acid leucine,” Haematologica, vol. 92, no. 5, pp. e66–e67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Jaako , S. Debnath, K. Olsson, J. Flygare, and S. Karlsson, “Bone marrow failure in RPS19-deficient mice is partly caused by p53 activation and responds to L-Leucine treatment,” in Proceedings of the 53nd Annual Meeting of the American-Society-of-Hematology (ASH '11), pp. 118–727, The American Society of Hematology, San Diego, Calif, USA, 2011.
  80. M. Soker, O. Ayyildiz, and A. Isikdogan, “Aase-Smith syndrome type II,” Saudi Medical Journal, vol. 25, no. 12, pp. 2004–2006, 2004. View at Google Scholar · View at Scopus
  81. E. Messa, D. Cilloni, F. Messa, F. Arruga, A. Roetto, and G. Saglio, “Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis,” Acta Haematologica, vol. 120, no. 2, pp. 70–74, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. G. L. Wang and G. L. Semenza, “Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction,” Blood, vol. 82, no. 12, pp. 3610–3615, 1993. View at Google Scholar · View at Scopus
  83. F. Saletta, Y. S. Rahmanto, E. Noulsri, and D. R. Richardson, “Iron chelator-mediated alterations in gene expression: identification of novel iron-regulated molecules that are molecular targets of hypoxia-inducible factor-1α and p53,” Molecular Pharmacology, vol. 77, no. 3, pp. 443–458, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. A. P. Russ and S. Lampel, “The druggable genome: an update,” Drug Discovery Today, vol. 10, no. 23-24, pp. 1607–1610, 2005. View at Publisher · View at Google Scholar · View at Scopus